Alnylam Pharmaceuticals
Quarterly Financials
| Values in thousands | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
|---|---|---|---|---|
Revenue | $420,146 | $659,825 | $494,333 | $439,718 |
Gross Profit | 416,221 | 591,153 | 428,357 | 353,860 |
EBITDA | -76,905 | 63,617 | -29,918 | -102,922 |
EBIT | 48,614 | -43,435 | -116,404 | |
Net Income | -111,570 | -16,889 | -65,935 | -137,870 |
Net Change In Cash | 420,146 | 659,825 | 494,333 | 439,718 |
Free Cash Flow | 39,515 | 116,140 | -94,488 | -45,104 |
Cash | 1,099,920 | 968,492 | 681,879 | 812,688 |
Basic Shares | 128,590 | 126,733 | 126,138 | 125,613 |
Annual Financials
| Values in thousands | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 |
|---|---|---|---|---|
Revenue | $1,828,292 | $1,037,418 | $844,287 | $492,853 |
Gross Profit | 1,517,886 | 868,601 | 704,143 | 414,801 |
EBITDA | -228,121 | -894,439 | -709,123 | -771,104 |
EBIT | -282,175 | -938,907 | -756,690 | -805,876 |
Net Income | -440,242 | -1,131,156 | -852,824 | -858,281 |
Net Change In Cash | 1,828,292 | 1,037,418 | 844,287 | 492,853 |
Cost of Revenue | 53,833 | 332,125 | -55,500 | |
Free Cash Flow | 41,945 | -613,333 | -718,065 | -685,322 |
Cash | 812,688 | 866,394 | 819,975 | 496,580 |
Basic Shares | 124,906 | 121,689 | 118,451 | 114,986 |
Earnings Calls
| Quarter | EPS |
|---|---|
2024-09-30 | -$0.87 |
2024-06-30 | -$0.13 |
2024-03-31 | -$0.52 |
2023-12-31 | -$1.10 |
